Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2013 May;57(5):2405–2409. doi: 10.1128/AAC.02063-12

Mechanism of Action of Efinaconazole, a Novel Triazole Antifungal Agent

Yoshiyuki Tatsumi a,, Maria Nagashima a, Toshiyuki Shibanushi b, Atsushi Iwata a, Yumi Kangawa b, Fumie Inui a, William J Jo Siu c, Radhakrishnan Pillai c, Yayoi Nishiyama d
PMCID: PMC3632939  PMID: 23459486

Abstract

The mechanism of action of efinaconazole, a new triazole antifungal, was investigated with Trichophyton mentagrophytes and Candida albicans. Efinaconazole dose-dependently decreased ergosterol production and accumulated 4,4-dimethylsterols and 4α-methylsterols at concentrations below its MICs. Efinaconazole induced morphological and ultrastructural changes in T. mentagrophytes hyphae that became more prominent with increasing drug concentrations. In conclusion, the primary mechanism of action of efinaconazole is blockage of ergosterol biosynthesis, presumably through sterol 14α-demethylase inhibition, leading to secondary degenerative changes.

TEXT

Ergosterol is an important structural component of fungal cell membranes, maintaining membrane fluidity and a permeability barrier, and is essential for fungal cell viability (13). Several classes of antifungal drugs target ergosterol biosynthesis. Among these, triazole antifungals (e.g., itraconazole) and imidazole antifungals (e.g., clotrimazole and miconazole) inhibit sterol 14α-demethylase (14-DM) in the ergosterol biosynthesis pathway (4). The consequent ergosterol depletion affects cell membrane integrity and function and is believed to inhibit fungal cell growth and affect morphology.

Efinaconazole, a novel triazole antifungal drug currently under development as a topical treatment for onychomycosis, has demonstrated efficacy in patients with toenail onychomycosis in two phase 3 clinical trials (5). Onychomycosis and other superficial mycoses are caused mainly by dermatophytes (e.g., Trichophyton rubrum and Trichophyton mentagrophytes) and yeast (e.g., Candida albicans). Efinaconazole possesses similar or higher antifungal activity against T. rubrum and T. mentagrophytes (MIC range, 0.00098 to 0.031 μg/ml) and a broader spectrum of activity than those of currently marketed antifungals used in onychomycosis (6). We investigated the effects of efinaconazole on fungal ergosterol biosynthesis and dermatophyte hyphal morphology.

In the present study, T. mentagrophytes strain SM-110 and C. albicans strain ATCC 10231 were used. The MICs of efinaconazole (Kaken Pharmaceutical), itraconazole, and clotrimazole (Sigma-Aldrich) were determined by the broth microdilution method using morpholinepropanesulfonic acid (MOPS)-buffered RPMI 1640, as described in CLSI documents M38-A2 (7) and M27-A3 (8), using visual endpoint readings of 80% growth inhibition at 4 days and 50% growth inhibition at 48 h, respectively. Efinaconazole was 4-fold more active than itraconazole against T. mentagrophytes SM-110 (MICs of 0.0039 and 0.016 μg/ml, respectively). Similarly, efinaconazole was 8-fold more active than clotrimazole against C. albicans ATCC 10231 (MICs of 0.00098 and 0.0078 μg/ml, respectively). The two strains showed typical susceptibilities to the antifungals tested, consistent with previous findings for these species (6, 9).

Ergosterol biosynthesis assays were conducted by modifying the methods of Vanden Bossche et al. (10) and Ryder et al. (11). T. mentagrophytes (2 × 108 microconidia/ml) and C. albicans (1 × 105 cells/ml) were exposed to drugs in MOPS-buffered RPMI 1640 medium containing [1,2-14C]sodium acetate at 0.4 μCi/ml and cultured at 35°C for 24 h with shaking. After culture, cells were subjected to a saponification treatment with a 50% ethanol solution containing 15% potassium hydroxide and 0.1% pyrogallol at 80°C for 2 h. Nonsaponified lipids were then extracted and separated by thin-layer chromatography using heptane-diisopropylether-acetic acid (60:40:4 [vol/vol/vol]) as a developing solvent. Incorporation of radioactivity into cell membrane lipids (i.e., 4-desmethylsterols [ergosterol], 4,4-dimethylsterols [lanosterol], 4α-methylsterols, and squalene) was measured using a liquid scintillation counter. In both fungal strains, efinaconazole decreased the radioactivity of the 4-desmethylsterol fraction and increased the radioactivity of the 4,4-dimethylsterol fraction in a dose-dependent manner at concentrations below its MICs (Fig. 1A). The increase in radioactivity of the 4α-methylsterol fraction was minimal, while there was essentially no change in squalene fraction radioactivity. The increase in 14-DM substrates (4,4-dimethylsterols and 4α-methylsterols) and decrease in 4-desmethylsterols suggest that efinaconazole, like other azoles, inhibits 14-DM.

Fig 1.

Fig 1

Effect of efinaconazole on ergosterol biosynthesis in T. mentagrophytes and C. albicans. (A) Effect of efinaconazole on [14C]acetate incorporation into cell membrane lipids. Incorporation of radioactivity into each lipid component (●, 4-desmethylsterols [ergosterol]; □, 4α-methylsterols; △, 4,4-dimethylsterols [lanosterol]; ×, squalene) is expressed as a percentage of the total radioactivity in all four lipid components. (B) Effects of efinaconazole, itraconazole, and clotrimazole on ergosterol biosynthesis. Efinaconazole (●) was compared to itraconazole (○) or clotrimazole (△) in T. mentagrophytes or C. albicans, respectively. Ergosterol biosynthesis is expressed as a percentage of the radioactivity incorporated in the 4-desmethylsterol fraction of untreated control cultures. Each symbol represents the mean for duplicate cultures of T. mentagrophytes or data for a single culture of C. albicans.

Efinaconazole was 4.9 times more active than itraconazole in inhibiting ergosterol biosynthesis in T. mentagrophytes (Fig. 1B); the 50% inhibitory concentrations (IC50) were 0.0070 (1.8× MIC) and 0.0338 (2.2× MIC) μg/ml, respectively. Similarly, efinaconazole was 7.3 times more active than clotrimazole in C. albicans (Fig. 1B); the IC50s were 0.00040 (0.41× MIC) and 0.0029 (0.37× MIC) μg/ml, respectively. Efinaconazole IC50s in the two fungal species were comparable to their corresponding MICs. Therefore, the potent in vitro antifungal activity of efinaconazole can be explained by its strong inhibition of ergosterol biosynthesis.

Ergosterol depletion and 14α-methylsterol accumulation resulting from 14-DM inhibition interfere with the “bulk” functions of ergosterol in fungal cell membranes (12). This leads to alterations in membrane fluidity and activities of several membrane-bound enzymes (e.g., chitin synthase) (12), which may induce cell membrane damage and morphological changes. The effect of efinaconazole on T. mentagrophytes hyphal morphology was therefore investigated. T. mentagrophytes (2 × 104 microconidia/ml) was cultured in Sabouraud dextrose broth at 30°C for 24 h with shaking. After conidia germinated, efinaconazole was added to the medium, and cultures were incubated for an additional 24 h. Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) analysis of the hyphae was performed as described by Nishiyama et al. (13), with minor modifications, using 2.5% glutaraldehyde for sample fixation and osmium tetroxide for SEM sample coating. Efinaconazole induced notable morphological and ultrastructural changes in hyphae (Fig. 2A and B). At concentrations ranging from 0.001 to 0.01 μg/ml, shortening of interseptal distance, globular swelling, and thickening of the cell wall were observed. Additionally, at concentrations ranging from 0.1 to 10 μg/ml, nonuniform widths and flattening of hyphae, separation of plasma membrane from the cell wall, accumulation of electron-dense granules in the space between the cell wall and the plasma membrane, discontinuity of the plasma membrane, and degeneration of organelles were observed. These changes became more prominent with increasing drug concentrations. Except for globular swelling, these changes have been previously found in Trichophyton species treated with other azoles, including bifonazole (14), itraconazole (15), and lanoconazole (16). Globular swelling was unique to efinaconazole treatment; however, its biological significance is unknown.

Fig 2.

Fig 2

Representative SEM and TEM images of T. mentagrophytes hyphae following 24 h of exposure to efinaconazole. Growth control (a), 0.001 μg/ml (b), 0.01 μg/ml (c), 0.1 μg/ml (d), 1 μg/ml (e), and 10 μg/ml (f) are shown. (A) Morphological changes included shortening of interseptal distance (b and c, arrows), globular swelling (b and c, arrowheads), nonuniform widths (d and e, double arrows), and flattening (d, e, and f, asterisks). S, septum. Bar, 1 μm. (B) Ultrastructural changes included thickening of the cell wall (b, c, and d, arrowheads), separation of the plasma membrane from the cell wall (c, d, e, and f, asterisks), accumulation of electron-dense granules in the space between the cell wall and the plasma membrane (d, e, and f, arrows), and discontinuity of the plasma membrane (d, e, and f, double arrows). CW, cell wall; PM, plasma membrane; N, nucleus; M, mitochondria. Bar, 200 nm.

Morphological and ultrastructural changes were observed at much lower efinaconazole concentrations than the previously reported MIC (0.2 μg/ml) for this test strain in Sabouraud dextrose broth (17). The highly electron-dense granules observed in the space between the cell wall and plasma membrane were considered to be lipid materials accumulated as a result of 14-DM inhibition, as suggested with itraconazole (15), lanoconazole (16), and neticonazole (18). These observations may be related to ergosterol biosynthesis inhibition.

Further, hyphal flattening, plasma membrane discontinuity, and degeneration of intracytoplasmic organelles produced at efinaconazole concentrations of 0.1 μg/ml or higher are likely associated with loss of viability and cell death. Indeed, we have previously reported that efinaconazole was fungicidal against 28 T. mentagrophytes strains in Sabouraud dextrose broth, with an 80% minimum fungicidal concentration (MFC80) of 0.25 μg/ml (19).

Antifungals such as miconazole (20, 21), clotrimazole (21), sertaconazole (22), and butenafine (23) have been reported to quickly damage fungal cell membranes through direct physicochemical interactions (within 1 h of drug treatment). However, because these effects were generally observed at concentrations several thousand times higher than the drugs' MICs, they are believed to be unrelated to the primary mechanism of action. To examine if efinaconazole could directly damage fungal cell membranes via the same mechanism, intracellular phosphate (Pi) leakage was measured using the method previously described by Iwatani et al. (23), with minor modifications. The efinaconazole concentrations for this assay were set at 0.1 to 100 μg/ml to evaluate the contribution of direct-membrane damage to the T. mentagrophytes hyphal changes observed at 0.1 to 10 μg/ml. T. mentagrophytes (1 × 107 hyphae/ml) was exposed to efinaconazole or miconazole (LKT Laboratories) in physiological saline at 30°C for 2 h with shaking. C. albicans (1 × 109 cells/ml) was exposed to efinaconazole or butenafine (Kaken Pharmaceutical) in distilled water at 35°C for 1 h with shaking. The positive controls, miconazole and butenafine, caused significant leakage of intracellular Pi at 40 and 100 μg/ml, respectively (Fig. 3), consistent with previous results (21, 23). In contrast, efinaconazole produced minimal Pi leakage at concentrations as high as 100 μg/ml (Fig. 3), suggesting that it does not have a direct fungal cell membrane-damaging effect. The short incubation time point (2 h) was needed to determine the existence of a direct, acute damage to the cell membrane. The electron microscopy observations after treatment with efinaconazole (≤10 μg/ml) for 24 h suggest an effect on cell membrane integrity, and thus, Pi leakage cannot be excluded at later time points as an indirect effect of ergosterol biosynthesis inhibition.

Fig 3.

Fig 3

Effect of efinaconazole and positive-control drugs on Pi leakage from T. mentagrophytes and C. albicans cells. Each bar represents the mean + SEM for triplicate cultures of T. mentagrophytes or data for a single culture of C. albicans.

In conclusion, the mechanism of antifungal action of efinaconazole is blockage of ergosterol biosynthesis by inhibiting 14-DM. The resulting ergosterol depletion and accumulation of precursor sterols may secondarily affect cell membrane integrity and function, leading to degenerative morphological changes.

ACKNOWLEDGMENTS

We thank Brian Bulley, Linda Mutter, Jun Nakano, and Hisato Senda for manuscript discussions and review and Shigeru Fujita for providing T. mentagrophytes strain SM-110.

Footnotes

Published ahead of print 4 March 2013

REFERENCES

  • 1. Rodriguez RJ, Low C, Bottema CDK, Parks LW. 1985. Multiple functions for sterols in Saccharomyces cerevisiae. Biochim. Biophys. Acta 837:336–343 [DOI] [PubMed] [Google Scholar]
  • 2. Nozawa Y, Morita T. 1986. Molecular mechanisms of antifungal agents associated with membrane ergosterol, dysfunction of membrane and inhibition of ergosterol biosynthesis, p 111–122 In Iwata K, Vanden Bossche H. (ed), In vitro and in vivo evaluation of antifungal agents: international symposium proceedings. Elsevier Science Publishers, Amsterdam, The Netherlands [Google Scholar]
  • 3. Parks LW, Smith SJ, Crowly JH. 1995. Biochemical and physiological effects of sterol alterations in yeast—a review. Lipids 30:227–230 [DOI] [PubMed] [Google Scholar]
  • 4. Sheehan DJ, Hitchcock CA, Sibley CM. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40–79 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, Ieda C, Smith K, Pillai R, Ramakrishna T, Olin JT. 2012. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J. Am. Acad. Dermatol. doi:10.1016/j.jaad.2012.10.013 [DOI] [PubMed] [Google Scholar]
  • 6. Jo Siu WJ, Tatsumi Y, Senda H, Pillai R, Nakamura T, Sone D, Fothergill A. 14 January 2013. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob. Agents Chemother. doi:10.1128/AAC.02056-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Clinical and Laboratory Standards Institute 2008. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA [Google Scholar]
  • 8. Clinical and Laboratory Standards Institute 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA [Google Scholar]
  • 9. Liu W, Zhang X, Liu Z, Luo X. 2011. Impact of pH on the antifungal susceptibility of vaginal Candida albicans. Int. J. Gynaecol. Obstet. 114:278–280 [DOI] [PubMed] [Google Scholar]
  • 10. Vanden Bossche H, Ausma J, Bohets H, Vermuyten K, Willemsens G, Marichal P, Meerpoel L, Odds F, Borgers M. 2004. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob. Agents Chemother. 48:3272–3278 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Ryder NS, Seidl G, Troke PF. 1984. Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans. Antimicrob. Agents Chemother. 25:483–487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Maetens JA. 2004. History of the development of azole derivatives. Clin. Microbiol. Infect. 10(Suppl 1):1–10 [DOI] [PubMed] [Google Scholar]
  • 13. Nishiyama Y, Hasumi Y, Ueda K, Uchida K, Yamaguchi H. 2005. Effects of micafungin on the morphology of Aspergillus fumigatus. J. Electron Microsc. (Tokyo) 54:67–77 [DOI] [PubMed] [Google Scholar]
  • 14. Osumi M, Yamada N, Yamada Y, Yamaguchi H. 1984. The effect of bifonazole on the structure of Trichophyton mentagrophytes. Dermatologica 169(Suppl 1):19–31 [PubMed] [Google Scholar]
  • 15. Borgers M, Van de Ven MA. 1987. Degenerative changes in fungi after itraconazole treatment. Rev. Infect. Dis. 9(Suppl 1):S33–S42 [DOI] [PubMed] [Google Scholar]
  • 16. Tameike A, Konomi M, Sato M, Ishijima S, Niwano Y, Osumi M. 1996. Structural effects of lanoconazole on the hyphal growth of Trichophyton rubrum. Jpn. J. Med. Mycol. 37:251–261 [Google Scholar]
  • 17. Tatsumi Y, Yokoo M, Senda H, Kakehi K. 2002. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob. Agents Chemother. 46:3797–3801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Nishiyama Y, Maebashi K, Asagi Y, Hiratani T, Yamaguchi H, Yamada N, Taki A, Ji XR, Osumi M. 1991. Effect of SS717 on the ultrastructure of Trichophyton mentagrophytes as observed by scanning and transmission electron microscopy. J. Med. Mycol. 32:43–54 [Google Scholar]
  • 19. Tatsumi Y, Yokoo M, Arika T, Yamaguchi H. 2001. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob. Agents Chemother. 45:1493–1499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Beggs WH. 1983. Comparison of miconazole- and ketoconazole-induced release of K+ from Candida species. J. Antimicrob. Chemother. 11:381–383 [DOI] [PubMed] [Google Scholar]
  • 21. Scott EM, Gorman SP, Millership JS, Wright LR. 1986. Effect of miconazole and clotrimazole on K+ release and inhibition of ergosterol biosynthesis in Trichophyton mentagrophytes and related ultrastructural observations. J. Antimicrob. Chemother. 17:423–432 [DOI] [PubMed] [Google Scholar]
  • 22. Agut J, Palacin C, Salgado J, Casas E, Sacristan A, Ortiz JA. 1992. Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimittelforschung 42:721–724 [PubMed] [Google Scholar]
  • 23. Iwatani W, Arika T, Yamaguchi H. 1993. Two mechanisms of butenafine action in Candida albicans. Antimicrob. Agents Chemother. 37:785–788 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES